Breaking News, Collaborations & Alliances

Emergent BioSolutions and Rocketvax Announce Investment Agreement

As part of the investment, Emergent would lead U.S. manufacturing and commercialization efforts for four of Rocketvax’s pipeline candidates.

By: Rachel Klemovitch

Assistant Editor

Emergent BioSolutions Inc., a specialty biopharmaceutical company headquartered in Gaithersburg, MD, and Rocketvax Ltd, one of Switzerland’s next-generation vaccine companies and a member of the Swiss Rockets Ltd family of companies, have agreed to Emergent’s strategic financial investment into Swiss Rockets Ltd, the parent company of Rocketvax Ltd, to support research, infrastructure development, and the expansion of Swiss Rockets’ innovative biotechnology portfolio.  In addition to the inve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters